MRC Technology and IBP CAS Collaboration Yields Humanized Anti-CD146 Antibody
News Mar 20, 2013
MRC Technology has announced that it has successfully humanized an anti-CD146 monoclonal antibody.
The project forms part of an on-going collaboration between MRC Technology and the Institute of Biophysics, Chinese Academy of Sciences (IBP CAS) to develop the antibody as a cancer therapeutic.
The cell adhesion molecule CD146 plays a critical role in tumour angiogenesis, an essential process for cancer development and metastasis.
Researchers in the lab of Prof Xiyun Yan at IBP CAS developed an anti-CD146 monoclonal antibody that dramatically inhibits tumour angiogenesis, migration and invasion.
Humanization of the antibody is an essential step in the development of anti-CD146 as a therapeutic.
Dave Tapolczay, MRC Technology’s CEO said: “The IBP CAS is one of the world’s leading academic research institutions and we are very pleased with the results of this collaboration. We are hopeful that the positive evaluation results for the humanized antibody will prove to be a significant milestone in cancer therapy and the fight against the disease.”
MRC Technology has humanized over 50 antibodies to date, including two marketed products, Tysabri (natalizumab) and Actemra (tocilizumab).
A further six are in clinical trials (including vedolizumab) and two more in preclinical studies.
New Way Found to Boost Immunity in Fighting Cancer and InfectionsNews
Researchers have identified a key new mechanism that regulates the ability of T-cells of the immune system to react against foreign antigens and cancer.READ MORE
Enterome and Nestlé Health Sciences Launch New Diagnostics CompanyNews
Enterome and Nestlé Health Sciences join to create Microbiome Diagnostics Partners, a company that will enable the development and diagnostics for multiple diseases including inflammatory bowel diseases (IBD) and liver diseases.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018
EMBL Course: Techniques for Mammary Gland Research
Mar 05 - Mar 09, 2018
EMBL Course: Brillouin Microscopy: Emerging Tool for Probing Mechanical Properties of Living Cells
Jan 17 - Jan 19, 2018